RS2 Healthcare Partners Invests in KMM Group

KMM Group (KMM) has completed an investment by RS2 Healthcare Partners (RS2), a Boston-based private equity firm, the companies announced today. Neither party disclosed details about the financing.

In conjunction with the investment, J. Mark King has been appointed president and CEO. Co-Founder John Shegda will serve as chief technology officer, leading engineering and technology strategy, while Co-Founder Eric Wilhelm has been appointed executive vice president of Business Transformation & Organizational Capability, overseeing operational excellence and scalable growth. The leadership changes preserve continuity for customers, employees, and partners and position the company for continued growth and manufacturing excellence, executives said.

“KMM is an exceptional company, with an excellent reputation in the marketplace, highly specialized capabilities, a blue-chip customer base, and an extremely dedicated group of employees,” RS2 Healthcare Partners Co-Managing Partner Craig Stern said. “We are thrilled to partner with John, Eric, and Mark for the company’s next chapter.”

King is an industry veteran who has more than 30 years of medical device industry experience. He served as president and CEO of Tegra Medical, a medical device contract manufacturer and former portfolio company of RS2 Healthcare Partners. Before Tegra, King was president and CEO of Clinical Innovations, a developer of women’s health medical devices. In addition, he has held leadership positions at Baxter Healthcare, Cardinal Health, and Johnson and Johnson.

“KMM has earned customers’ trust by solving complex manufacturing challenges that many others simply cannot do,” King stated. “I am honored and excited to continue building on KMM’s momentum. I have a long history of working with the principals at RS2 Healthcare Partners as well as serving as an advisor to KMM. With this investment, I look forward to partnering with RS2, John, Eric, and the rest of the KMM team to expand the company’s capabilities and further strengthen its position as a premier contract manufacturer for medtech and other end markets.”

“Manufacturing is evolving rapidly, and our customers continue to push the boundaries of engineering,” Shegda commented. “My focus is to ensure KMM stays ahead of that curve by advancing our manufacturing technology, expanding our engineering expertise, and helping customers bring the next generation of life-changing medical technologies to market. We are thrilled to partner with RS2 and Mark to ensure that we deliver on our vision, uphold our mission, and continue to support our customers.”

“Our customers count on KMM to deliver quality, responsiveness and execution every day,” said Eric Wilhelm. “As we continue to grow, our priority is to strengthen every part of our operation while preserving the culture, accountability and manufacturing excellence that have always defined KMM. RS2 is the ideal partner for KMM, given the firm’s significant contract manufacturing expertise and deep experience scaling founder-owned companies.”

KMM Group is a contract manufacturer specializing in complex, tight-tolerance components for the medical device industry and other highly demanding markets. KMM solves complex, failure-intolerant engineering challenges through integrated capabilities, technical expertise, and scalable production.

Founded in 1989, RS2 Healthcare Partners (formerly Riverside Partners) is a private equity firm with total capital commitments of $1.6 billion raised since inception. The firm exclusively focuses on healthcare investing in the lower middle market. RS2 Healthcare Partners combines a disciplined investment strategy, specialized sector expertise, an experienced team of investment professionals and healthcare advisors, and a collaborative approach to partnering with founders and management teams.